Q3 2024 EPS Estimates for Syros Pharmaceuticals, Inc. Raised by HC Wainwright (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Analysts at HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for Syros Pharmaceuticals in a research note issued to investors on Thursday, August 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.72) for the quarter, up from their prior estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.94) EPS, FY2025 earnings at ($2.96) EPS, FY2026 earnings at ($2.28) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at $1.50 EPS.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 850.20%. During the same period in the previous year, the firm posted ($0.85) earnings per share.

Separately, StockNews.com upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 15th.

Syros Pharmaceuticals Stock Performance

Shares of Syros Pharmaceuticals stock opened at $5.35 on Monday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.46 and a quick ratio of 3.01. The firm has a 50 day simple moving average of $5.59 and a 200 day simple moving average of $5.91. Syros Pharmaceuticals has a fifty-two week low of $2.09 and a fifty-two week high of $8.17. The firm has a market cap of $143.43 million, a P/E ratio of -1.07 and a beta of 1.53.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $64,000. Acadian Asset Management LLC bought a new position in Syros Pharmaceuticals during the first quarter worth about $91,000. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter worth about $109,000. Assenagon Asset Management S.A. increased its stake in shares of Syros Pharmaceuticals by 576.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company’s stock valued at $909,000 after acquiring an additional 144,869 shares during the last quarter. Finally, Opaleye Management Inc. acquired a new stake in shares of Syros Pharmaceuticals in the 4th quarter valued at approximately $2,799,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

Insiders Place Their Bets

In other news, Director Richard A. Young sold 34,837 shares of Syros Pharmaceuticals stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $5.12, for a total transaction of $178,365.44. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at approximately $40,960. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 12.26% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.